Atezolizumab First PD-L1 Inhibitor Approved for the Treatment of Patients with Metastatic NSCLC

Online First - FDA News & Updates
On October 18, 2016, atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, was approved by the FDA for patients with metastatic non–small-cell lung cancer (NSCLC) associated with the EGFR or ALK genetic mutations whose disease progressed during or after treatment with platinum-containing chemotherapy.
Related Items
Sustol, First Extended-Release 5-HT3 Approved for the Prevention of CINV
Online First published on November 11, 2016 in FDA News & Updates
Cabometyx Receives FDA Approval for Advanced Renal-Cell Carcinoma
Online First published on November 11, 2016 in FDA News & Updates
Olaratumab Approved for Use with Doxorubicin in Adults with Advanced Soft-Tissue Sarcoma
Online First published on October 31, 2016 in FDA News & Updates, Online First
Last modified: October 31, 2016